Aro Biotherapeutics Expands Leadership Team with Addition of Proven Scientific Executives

PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that Adam Dinerman, Ph.D. and John Liu, Ph.D. have joined the company as Executive Director, Head of Chemistry, Manufacturing and Controls (CMC) and Vice President, Biology, respectively.

“The addition of top talent with deep functional experience is a critical success driver for Aro as we enter our next phase of growth,” stated Sue Dillon, Ph.D., co-founder and Chief Executive Officer of Aro Biotherapeutics. “We are very excited that Adam and John are joining our company, and are confident that they will both add tremendous value to our organization as our pipeline and platform continue to advance.”

Adam Dinerman, Ph.D., brings over twenty years of experience in pharmaceutical development, technology transfer, and manufacturing to Aro Biotherapeutics. As a CMC Leader at Johnson & Johnson (Janssen R&D), Adam led multiple early and late stage CMC programs across different therapeutic areas for a variety of biotechnology products including monoclonal antibodies (“mAbs”), bi specific mAbs, fusion proteins, and gene therapy products for rare diseases. Prior to holding the CMC Leader position, Adam took on roles of increasing responsibility within the drug product development group at Janssen R&D and also contributed to multiple IND/CTA and BLA submissions during his tenure. Prior to Johnson & Johnson, Adam worked at Genzyme in bioprocess development. Adam received his Ph.D. in Pharmaceutical Sciences from the University of Maryland at Baltimore.

Zhonghao (John) Liu, Ph.D., has more than 13 years of experience in small molecule, recombinant protein and antibody therapeutics development across a wide array of human diseases including diabetes, obesity, dyslipidemia, ophthalmology, NASH, and inflammatory disorders. John was most recently Director of Biology at NGM Biopharmaceuticals, with responsibility for leading the company’s target discovery and large molecule drug discovery efforts. Earlier in his career, John was an integral member of the team at Metabolex Inc., a company pursuing small molecule therapeutics targeting the G protein-coupled receptors (GPCR). Over the course of his career, John has led teams that have successfully progressed multiple drug candidates into clinical development. John received a Ph.D. in Developmental Biology from Washington University in St. Louis and completed post-doctoral training in diabetes research at Washington University School of Medicine.

About Aro Biotherapeutics

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases. For more information, visit www.arobiotx.com.